Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Core Insights - Calidi Biotherapeutics has appointed Dr. Mark Gilbert, a prominent figure in neuro-oncology, to its Medical Advisory Board, enhancing the board's expertise and membership to eight [9][10]. Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using proprietary technology to enhance the immune system's ability to combat cancer [6]. - The company utilizes allogeneic stem cells to deliver oncolytic viruses, aiming to treat various oncology indications, including high-grade gliomas and solid tumors [6]. Dr. Mark Gilbert's Background - Dr. Gilbert served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024, where he led significant research in brain tumors and developed innovative clinical trials [2][4]. - His experience includes working at renowned institutions such as MD Anderson and Johns Hopkins, where he completed his medical training and residencies [4]. Potential Impact of Dr. Gilbert's Appointment - Dr. Gilbert expressed enthusiasm for Calidi's therapies, particularly their versatility in addressing rare cancer diseases that affect approximately 25% of cancer patients [3]. - The CEO of Calidi, Allan Camaisa, highlighted that Dr. Gilbert's expertise will guide the company in developing innovative studies and partnerships with national centers of excellence [11].